RT @_Castillo_Pedro: Upadacitinib 56-wk efficacy/safety (mod to severe PsA) ð¹Comparable or â¬ï¸efficacy vs adalimum
Tweet Content
Upadacitinib 56-wk efficacy/safety (mod to severe PsA)
🔹Comparable or ⬆️efficacy vs adalimumab
🔹Efficacy maintained, and 15mg vs 30mg doses similar at 56wks
🔹No new safety findings @ 56wks
🔹🚫inc risk VTE, MACE, cancer vs ada
https://t.co/NlKvBrwDxB
#ACR21 Abst#1345 @RheumNow
Links
Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic A…
https://bit.ly/3H1BAjn
Show on Archive Page
On
Display in Search Results
On
PDQ
Off